Ophthalmic Drug CDMO Market Size, Forecast by 2034

The global ophthalmic drug CDMO (Contract Development and Manufacturing Organization) market is poised for transformative growth from 2025 to 2034, underpinned by innovation in sterile manufacturing, increasing outsourcing strategies, and the rising prevalence of eye disorders. The market is expected to expand at a robust CAGR through the forecast period, as pharmaceutical and biotechnology companies increasingly rely on CDMOs to accelerate drug development, ensure compliance with stringent regulations, and scale production for complex ophthalmic formulations.

This growth is particularly fueled by advancements in drug delivery systems, such as inserts and implants, and the adoption of artificial intelligence (AI) for drug discovery, predictive modeling, and clinical trial optimization.

Quick Insights

• Base Year: 2024

• Forecast Period: 2025–2034

• Dominating Region: North America

• Fastest Growing Region: Asia Pacific

• Top Service Segment: Drug product manufacturing (formulation & fill-finish)

• Emerging Service Segment: Analytical & regulatory services

• Leading Dosage Form: Eye drops & solutions

• Fastest-Growing Dosage Form: Inserts & implants

• Top Molecule Type: Small molecules

• Fastest-Growing Molecule Type: Biologics

• Leading Therapeutic Area: Glaucoma

• Fastest-Growing Therapeutic Area: Retinal disorders (AMD, DME, etc.)

• Top End User: Large pharmaceutical companies

• Fastest-Growing End User: Biotechnology firms

• Key Players: Catalent, Lonza, Recipharm, Siegfried Holding AG, WuXi AppTec, Thermo Fisher Scientific, Bausch + Lomb, Alcon.

Get a Sample: https://www.precedenceresearch.com/sample/6690

Market Dynamics: What Is Driving Growth?

The ophthalmic drug CDMO market is propelled by three converging forces:

1. Rising Prevalence of Eye Disorders: Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and dry eye disease are creating unprecedented demand for innovative treatments.

2. Outsourcing Imperative: Pharmaceutical and biotech companies are increasingly outsourcing ophthalmic drug development to reduce costs, mitigate regulatory risks, and leverage specialized CDMO expertise.

3. Technological Leap: AI, automation, nanoparticle-based drug delivery, and advanced sterile manufacturing have emerged as transformative enablers for ophthalmic therapies.

However, stringent global regulatory standards and high operational costs continue to act as barriers for smaller CDMOs entering this highly specialized market.

Opportunity and Trend: Can AI and Gene Therapies Redefine Ophthalmic Drug Development?

One of the most significant opportunities lies in the integration of AI and gene therapy platforms within CDMO operations. AI-driven predictive models can shorten drug discovery cycles and optimize formulation stability, while gene therapy manufacturing capabilities unlock entirely new treatment avenues for inherited retinal disorders and other rare ophthalmic conditions.

CDMOs that can offer end-to-end solutions — spanning gene therapies, biologics, and sustained-release implants — are positioned to become the industry’s most critical partners in addressing high unmet medical need.

Expert Insight

“The ophthalmic drug CDMO market is at a strategic inflection point. Pharmaceutical companies increasingly seek specialized partners who can not only meet sterile manufacturing standards but also drive innovation in biologics, gene therapies, and AI-enabled analytics. Those CDMOs that offer integrated, end-to-end solutions will define the next decade of ophthalmic healthcare.”

— Dr. Anjali Mehra, Principal Consultant, Precedence Research

Market Scope

Segmentation Analysis

Service Type

• Drug Product Manufacturing (Formulation & Fill-Finish): Leading the market in 2024, this segment is critical for sterile ophthalmic solutions, ointments, and implants.

• Analytical & Regulatory Services: Expected to grow at the fastest CAGR as global regulatory compliance becomes increasingly complex.

Dosage Form

• Eye Drops & Solutions: Dominated 2024 due to high patient preference and cost-effectiveness.

• Inserts & Implants: Forecast to grow fastest, with demand for sustained-release therapies in chronic conditions like AMD and glaucoma.

Molecule Type

• Small Molecules: Maintained the largest share in 2024 due to broad therapeutic applications.

• Biologics: Anticipated to be the fastest-growing category, especially with monoclonal antibodies and gene therapies advancing in ophthalmology.

Therapeutic Area

• Glaucoma: Remains the largest market segment in 2024, supported by a growing elderly population.

• Retinal Disorders: Fastest-growing segment, driven by anti-VEGF therapies, biologics, and gene therapy pipelines.

End User

• Large Pharmaceutical Companies: Continue to dominate by leveraging CDMO partnerships to remain asset-light.

• Biotechnology Firms: Fastest-growing due to reliance on CDMOs for specialized infrastructure and advanced manufacturing.

---

Regional Insights

North America: Market Leader

North America held the largest share in 2024, supported by advanced healthcare infrastructure, high R&D spending, and a strong regulatory framework. The U.S. market is defined by FDA-led quality standards and recent product launches like Viatris Inc.’s RYZUMVI™, an FDA-approved solution for reversing pharmacologically induced mydriasis.

Europe: Innovation-Driven

Europe’s CDMOs are leveraging their strong regulatory frameworks and advanced biologics capabilities. Countries like Germany and Switzerland serve as hubs for innovation in ophthalmic drug delivery systems.

Asia Pacific: Fastest-Growing Region

Asia Pacific is projected to witness the highest CAGR, driven by cost-effective manufacturing, rising healthcare expenditure, and supportive government incentives in China and India. The region is fast becoming a global hub for pharmaceutical outsourcing.

Latin America & Middle East & Africa

Emerging opportunities exist in these regions, where a rising patient population with untreated ophthalmic disorders is creating unmet demand for affordable ophthalmic solutions.

Breakthroughs and Recent Developments

• Alcon (July 2025): Announced acquisition of LumiThera, Inc., strengthening its pipeline in light-based therapy for AMD.

• Alcon (Aug 2025): Entered a definitive merger agreement to acquire STAAR Surgical for $1.5 billion, expanding into myopia treatments.

• Glenmark Pharmaceuticals (Feb 2025): Launched Latanoprost Ophthalmic Solution 0.005%, expanding its ophthalmic product portfolio.

• Bausch + Lomb (June 2024): Introduced INFUSE for Astigmatism daily disposable contact lenses, addressing comfort and clarity challenges.

Challenges and Cost Pressures

The industry faces ongoing challenges including:

• Regulatory Complexity: Divergent compliance standards across FDA, EMA, and regional regulators.

• High Operational Costs: Investments in sterile manufacturing infrastructure and validation processes.

• Drug Delivery Complexity: Advanced dosage forms such as implants require precision manufacturing and strict sterility.

Case in Point: Sustained-Release Implants for Retinal Disorders

The development of long-acting ocular implants demonstrates the growing reliance on CDMOs. These systems reduce treatment frequency for patients with AMD and diabetic retinopathy, but they require specialized sterile environments, advanced polymer science, and regulatory expertise. CDMOs offering such niche capabilities are now indispensable to both large pharma and biotech firms.

Read Also: Enzyme Inhibitor Market Set to Reach USD 45.72 Billion by 2034, Amid AI-Driven Drug Discovery Surge

Call to Action

Precedence Research provides in-depth market intelligence on the ophthalmic drug CDMO industry, enabling stakeholders to make data-driven decisions on partnerships, investments, and strategic expansions.

📩 Download a Sample Report Here: Ophthalmic Drug CDMO Market Report
📅 Schedule a Consultation: Connect with our analysts to explore market opportunities and customized insights.